Table 3 Characteristics of included studies cont’d: phase of infection and funding source
From: Sensitivity and specificity of diagnostic tests for Lassa fever: a systematic review
Author Last | Test Name | Phase of infection | Funding source |
|---|---|---|---|
Boisen et al | Recombinant Lassa Virus Rapid Diagnostic Test (ReLASV RDT) | Acute phase | NIH (National Institute for Health). Possible conflict of interest with Viral Hemorrrhagic fever Consortium. |
Boisen et al | Recombinant Lassa Virus Antigen ELISA (ReLASV Ag ELISA) | NIH (National Institute for Health). Possible conflict of interest with Viral Hemorrrhagic fever Consortium. | |
Bausch et al | Combined ELISA Antigen/IgM assay | Acute phase. Convalescent samples collected but data on testing not given. | American Association of Schools of Public Health (AASPH) & Tulane University |
Indirect Immunofluorescent antibody test | |||
Gabriel et al | IgM ELISA | Not clear | European Fund for regional development |
IgM/IgG ELISA | |||
Ibekwe et al | IgM ELISA | Acute phase | No funding source |
Meulen et al. | IgM/IgG Immunoblot | Not clear | Not stated |
Emmerich et al | Reverse IgG ELISA | Convalescent samples (from survivors) | Bundesamt f¨ur Wehrtechnik und Beschaffung |
Olschlager et al | GPC RT-PCR(Qiagen) | Not clear | Bundesamt f¨ur Wehrtechnik und Beschaffung |
Trappier et al | Conventional PCR | Not clear | Not stated |